Multiple Endocrine Neoplasia Type 1

Slide 1 · Multiple endocrine neoplasia, type 1

Inherited predisposition to multifocal endocrine neoplasia

Pathology • Molecular mechanisms • Morphology • Clinical correlations

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Recognize the characteristic MEN1 organ distribution and its clinical consequences.

Explain how a germline MEN1 defect predisposes to multiple endocrine lesions.

Relate parathyroid, gastroenteropancreatic and pituitary lesions to their hormone syndromes.

Discriminate MEN1 from sporadic endocrine tumors and selected MEN phenocopies.

Slide 3 · MEN syndromes are systemic tumor predispositions

Inherited susceptibility

Endocrine-cell proliferation

Multifocal lesions in several organs

Hormone excess ± malignant behavior

Hyperplasia, adenomas, and carcinomas may coexist across the syndrome spectrum.

Slide 4 · Inherited endocrine tumors differ from sporadic tumors

Feature

MEN-associated pattern

Sporadic pattern

Age

Often earlier onset

More often later presentation

Distribution

More than one organ possible

Usually one organ

Focality

Multifocal within an organ

Often solitary

Chronology

Synchronous or metachronous

Usually isolated event

Slide 5 · MEN1 is Wermer syndrome

A rare inherited syndrome of endocrine proliferative lesions.

Textbook prevalence: Approximately 2 per 100,000.

The defining distribution is parathyroid, enteropancreatic endocrine tissue, and anterior pituitary.

Clinical illness reflects both hormone secretion and neoplastic behavior.

Slide 6 · The three Ps organize the MEN1 phenotype

Parathyroid

Primary hyperparathyroidism

Pancreas / duodenum

Neuroendocrine neoplasms

Pituitary

Prolactinoma; Other PitNETs

“Pancreatic” includes clinically important duodenal gastrinomas.

Slide 7 · MEN1 expression varies among organ systems

Organ group

Dominant abnormality

Major clinical signal

Parathyroid

Adenomas and/or hyperplasia

PTH-related hypercalcemia

Duodenum / pancreas

Often multifocal neuroendocrine neoplasms

Peptic ulcers or hypoglycemia

Anterior pituitary

Often lactotroph tumor

Prolactin-excess manifestations

Slide 8 · Multifocality is more informative than tumor size

One dominant lesion

Dominant focus

Multiple microscopic lesions

Scattered small foci

A clinically evident endocrine tumor may coexist with additional small lesions in the same organ.

Slide 9 · Synchronous and metachronous disease

Presentation

One symptomatic endocrine lesion

Subsequent evaluation

Other endocrine lesions recognized

Longitudinal course

Further lesions may develop

An apparently isolated initial lesion does not exclude a hereditary syndrome.

Slide 10 · Hormone excess and tumor burden are different axes

Local tumor extent / metastatic potential

Endocrine hypersecretion

Small but strongly secretory

Secretory and aggressive

Large but clinically nonfunctioning

Small without overt syndrome

Slide 11 · MEN1 encodes the tumor-suppressor-associated protein menin

MEN1 germline variant

Altered menin function

Disrupted transcriptional regulation

Endocrine neoplastic predisposition

Menin participates in several transcription factor complexes.

Slide 12 · Menin acts in context-dependent transcriptional complexes

Molecular fact

MEN1 encodes menin.

Menin associates with multiple transcription factor complexes.

Biological implication

Its effect depends on interacting partners.

Menin can promote or restrain tumorigenesis according to cellular context.

Slide 13 · Germline susceptibility is not the same as a visible tumor

Inherited MEN1 susceptibility

Cell- or tissue-specific additional changes

Clonal endocrine proliferation

Detectable hyperplasia or tumor

Conceptual tumor-suppressor model; No patient-specific mutation sequence implied.

Slide 14 · MEN1 mutations also occur in sporadic neoplasms

Hereditary MEN1 syndrome

Germline MEN1 defect.

Multi-organ tumor predisposition.

May show multiple lesions.

Sporadic endocrine neoplasm

MEN1 changes can arise somatically.

The genetic event may remain confined to one tumor.

A mutation in a tumor alone does not establish inherited MEN1.

Slide 15 · An organ-specific mutation does not establish MEN1

Sporadic parathyroid adenomas can harbor somatic MEN1 changes.

Some sporadic pancreatic neuroendocrine neoplasms also have MEN1 mutations.

Interpret family history, tumor distribution and germline status separately.

Do not equate tumor sequencing with germline predisposition.

Slide 16 · Family-based interpretation requires organ-level synthesis

Recognize an MEN1-like tumor pattern

Review personal and family endocrine histories

Distinguish germline from somatic findings

Coordinate endocrine and genetic evaluation

Framework for reasoning; No unverified surveillance interval or test threshold is prescribed.

Slide 17 · Parathyroid disease dominates MEN1 presentation

Primary hyperparathyroidism is the most common MEN1 manifestation.

Involvement in approximately 80%–95% of patients.

It is the first recognized manifestation in most affected individuals.

Near-universal appearance by about age 40–50 years.

Slide 18 · MEN1 parathyroid lesions include hyperplasia and adenomas

Hyperplasia

Expansion of parathyroid cellular mass.

Can involve several glands.

Autonomous PTH secretion may develop.

Adenoma

Discrete endocrine neoplasm.

May coexist with other proliferative lesions.

The MEN1 context alters expectations about focality.

Slide 19 · Autonomous PTH secretion produces primary hyperparathyroidism

Parathyroid overactivity

Excess PTH

Calcium mobilization / retention

Hypercalcemia with systemic sequelae

Mechanistic compression of textbook parathyroid physiology and disease.

Slide 20 · PTH has coordinated skeletal and renal actions

Target

Relevant action of PTH

Manifestation when excessive

Bone

Promotes osteoclastic bone resorption indirectly

Skeletal mineral loss

Kidney

Promotes calcium conservation

Contributes to higher serum calcium

Calcium balance

Raises circulating free calcium

Hypercalcemia and urinary stone risk

Slide 21 · Hypercalcemia may be clinically silent

Primary hyperparathyroidism is often first detected on routine chemistry testing.

Symptoms are not required for clinically significant endocrine disease.

A hypercalcemic patient needs an etiologic evaluation—not an assumption of MEN1.

Family history and additional endocrine lesions increase suspicion for a syndrome.

Slide 22 · PTH excess links MEN1 to nephrolithiasis

Parathyroid proliferative lesion

Persistent PTH excess

Increased blood calcium

Renal stone formation

Nephrolithiasis is an explicitly described MEN1-related clinical presentation.

Slide 23 · Sustained hyperparathyroidism can damage bone

PTH-associated bone resorption can lower skeletal mass.

Severe untreated disease may cause osteitis fibrosa cystica.

Brown tumors are reactive lesions following bone injury and hemorrhage.

These skeletal consequences are not themselves primary bone malignancies.

Slide 24 · Parathyroid morphology must be interpreted in context

Observation

What it indicates

What it cannot establish alone

Increased chief-cell density

Parathyroid proliferative lesion

Germline MEN1 status

Reduced stromal fat

May accompany hyperplasia/adenoma

Single vs multiple affected glands

Multiple enlarged glands

Suggests a multigland process

Specific syndrome without clinical context

Slide 25 · Sporadic solitary adenoma is the key comparator

Sporadic primary hyperparathyroidism

A solitary adenoma is the commonest cause.

Usually presents without additional syndromic endocrine tumors.

MEN1-associated hyperparathyroidism

Hyperplasia and adenomas occur.

Multigland involvement and other endocrine lesions strengthen suspicion.

Slide 26 · Parathyroid disease can obscure other MEN1 lesions

A younger adult presents with recurrent renal calculi, raised serum calcium and non-suppressed PTH.

What should the endocrine-pathology assessment not overlook?

The possibility of a syndromic cause if multifocal parathyroid disease, family history or another endocrine lesion is identified.

Slide 27 · Enteropancreatic neuroendocrine disease drives major risk

Gastroenteropancreatic endocrine tumors are a major source of MEN1 morbidity and mortality.

Clinically aggressive behavior in some MEN1 tumors.

Multiple microscopic lesions may coexist with one or two dominant masses.

Both hormonal syndromes and metastatic disease matter.

Slide 28 · Pancreatic multifocality is a characteristic pattern

Dominant lesion

Microadenomas

Small microadenomas can be distributed throughout the organ with one or more dominant lesions.

Slide 29 · PanNEN is the contemporary pathologic umbrella term

Pancreatic neuroendocrine neoplasms (PanNENs) arise from endocrine-lineage cells.

They may be functioning or clinically nonfunctioning.

Histologic differentiation and proliferation inform tumor classification.

MEN1-associated lesions must be interpreted within a hereditary, frequently multifocal setting.

Slide 30 · Differentiation, grade and hormone function are distinct

Domain

Key question

Not equivalent to

Differentiation

What neoplastic phenotype is present?

Whether hormone symptoms occur

Proliferation

How actively is the tumor growing?

Tumor anatomical multiplicity

Function

Is there a hormone-driven syndrome?

Guaranteed indolent behavior

Slide 31 · Not every secretory tumor creates a clinical syndrome

Tumor produces peptide

Hormone or peptide enters circulation

Biological activity varies

Symptoms may be absent despite secretion

Pancreatic polypeptide is often secreted in MEN1 but frequently has no overt hypersecretion syndrome.

Slide 32 · Pancreatic polypeptide illustrates “functional” ambiguity

MEN1-associated pancreatic endocrine neoplasms may elaborate pancreatic polypeptide.

Pancreatic polypeptide is often the predominant secretory product account.

A detectable secretory product need not yield a specific clinical hormone-excess syndrome.

Clinical functioning should be described separately from immunohistochemical expression.

Slide 33 · Gastrinoma frequently arises in the duodenum

Duodenum

Pancreas

Gastrinoma site

Pancreatic lesion

In MEN1 the duodenum is more often the site of gastrinomas than the pancreas; Both may occur together.

Slide 34 · Gastrin excess causes Zollinger–Ellison syndrome

Gastrin-producing neuroendocrine tumor

Increased gastrin

Marked gastric acid hypersecretion

Severe / recurrent peptic ulceration

Pathophysiologic clinical correlation grounded in pancreatic chapter and MEN1 discussion.

Slide 35 · Ulcer severity is an endocrine diagnostic clue

Gastrinoma-associated acid excess can cause intractable peptic ulcers.

Repeated or unusually severe ulcer disease invites consideration of a gastrin-secreting tumor.

In MEN1, duodenal location is particularly important.

A presumed pancreatic-only tumor search can miss clinically relevant lesions.

Slide 36 · Synchronous duodenal and pancreatic tumors are possible

Duodenal gastrinoma

Dominant focus

Pancreatic endocrine lesions

Scattered small foci

One MEN1 patient can harbor lesions at both sites; A single mass does not explain the entire risk.

Slide 37 · Insulinoma produces endogenous hyperinsulinism

Insulin-secreting neoplasm

Inappropriately high insulin

Low plasma glucose

Neuroglycopenic manifestations

Insulinoma is not established by hypoglycemia in isolation.

Slide 38 · Hypoglycemia explains insulinoma neurologic symptoms

Central nervous system function depends on glucose availability.

Severe low glucose may produce confusion, stupor or loss of consciousness.

Episodes often relate to fasting or exertion description.

Improvement after glucose is a clinical clue, not a stand-alone tumor diagnosis.

Slide 39 · Endogenous insulin secretion requires biochemical correlation

Finding during hypoglycemia

Diagnostic implication

Insulin not appropriately suppressed

Supports inappropriate insulin secretion

Elevated C-peptide

Supports endogenous rather than injected insulin

Clinical symptom pattern

Defines urgency and guides contextual evaluation

Alternative causes excluded

Avoids misclassifying nonneoplastic hypoglycemia

Slide 40 · An insulinoma differential prevents false attribution

Adrenal insufficiency and advanced liver disease may cause hypoglycemia.

Drug-related hypoglycemia, including sulfonylureas, is an important alternative.

Exogenous insulin administration requires separate consideration.

MEN1 status does not remove the need for biochemical confirmation.

Slide 41 · Morphology alone cannot reliably determine PanNEN behavior

Microscopic appearance

May appear monotonous and well differentiated.

A low-power bland appearance can be deceptive.

Behavioral assessment

Consider mitotic activity / Ki-67 in appropriate contexts.

Evaluate extent, invasion and metastasis.

Integrate disease site and clinical course.

Slide 42 · The dominant mass is not the whole pancreatic disease

In an MEN1 carrier, imaging demonstrates one sizable pancreatic lesion; Additional small lesions are described in the resection.

How should the specimen and clinical imaging be conceptualized?

As potentially multifocal endocrine neoplasia, with individual lesions requiring morphologic and clinical characterization.

Slide 43 · The three endocrine presentations demand different tests

Syndrome

Dominant clinical problem

Biochemical concept

Hyperparathyroidism

Hypercalcemia / stones

Serum calcium with PTH context

Gastrinoma

Acid hypersecretion / ulceration

Inappropriately increased gastrin

Insulinoma

Hypoglycemia / neuroglycopenia

Insulin and C-peptide during hypoglycemia

Slide 44 · Pituitary tumors complete the MEN1 triad

The anterior pituitary is the third major endocrine site in MEN1.

The most frequently encountered pituitary lesion is a prolactinoma.

Somatotropin-secreting tumors may produce acromegaly.

Clinical findings may reflect hormonal secretion or local mass effect.

Slide 45 · Prolactinoma causes an endocrine syndrome

Lactotroph pituitary tumor

Excess prolactin

Reproductive axis disruption

Amenorrhea, galactorrhea, infertility or sexual dysfunction

Clinical phenotype depends on sex, age and reproductive context.

Slide 46 · Prolactin excess is not specific to prolactinoma

Alternative source of hyperprolactinemia

Interpretive implication

Pregnancy / lactation

Physiologic elevation

Pituitary stalk interference

Loss of hypothalamic dopamine inhibition

Dopamine-antagonist drugs

Pharmacologic disinhibition

Renal failure / hypothyroidism

Systemic causes of raised prolactin

Slide 47 · A pituitary mass may manifest by mass effect

Expanding lesions can extend beyond the sella.

Compression of the optic apparatus may disturb visual fields.

Larger tumors may impair normal pituitary function.

Hormone secretion and lesion size should be assessed as separate issues.

Slide 48 · Somatotroph tumors cause GH-related tissue growth

Somatotroph pituitary neoplasm

Excess growth hormone

Increased hepatic IGF-1

Acromegalic changes in adults

The clinical syndrome depends on developmental timing.

Slide 49 · Acromegaly translates biochemistry into morphology

After epiphyseal closure, GH/IGF-1 excess enlarges acral soft tissues and bone.

Characteristic changes include broadening hands, feet and facial structures.

The syndrome may evolve insidiously before tumor diagnosis.

The MEN1 clinical context is relevant when acromegaly accompanies other endocrine disease.

Slide 50 · Pituitary morphology requires lineage integration

Assessment axis

Pathology contribution

Architecture

Monomorphic cell population with altered reticulin network

Hormone expression

PRL and GH can support relevant functional subtypes

Cell lineage

Lineage-associated transcription factors aid classification

Clinical state

Hormone phenotype and mass effects remain indispensable

Slide 51 · A pituitary tumor need not be the presenting lesion

A person treated for primary hyperparathyroidism later develops galactorrhea and biochemical prolactin excess.

What unifying interpretation should be considered?

Multiple endocrine neoplasia type 1, while excluding other causes of hyperprolactinemia and confirming the pituitary lesion.

Slide 52 · MEN1 extends beyond the three Ps

Additional site / finding

Textbook relationship

Duodenum

Common gastrinoma site

Other neuroendocrine (carcinoid) tumors

Increased occurrence

Thyroid / adrenal cortex

Adenomas occur more frequently

Soft tissue

Lipomas more frequent than population background

Slide 53 · Additional lesions are clues, not defining substitutes

A lipoma or thyroid adenoma is common and nonspecific in isolation.

The significance rises when it accompanies a characteristic endocrine triad lesion.

Multisite interpretation is more informative than any single incidental lesion.

Avoid overdiagnosing MEN1 based on one low-specificity finding.

Slide 54 · The endocrine phenotype can change over time

Early finding

Hyperparathyroidism may be first

Further evaluation

Duodenal/pancreatic or pituitary tumors detected

Later course

Hormone syndromes or malignant progression may emerge

Illustrative possible sequence; Not an individual-level prediction.

Slide 55 · MEN1 can cause both morbidity and mortality

Tumor growth and spread

Hormonal bioactivity

PTH-related organ injury

Secreting metastatic tumor

Nonfunctioning aggressive tumor

Indolent silent lesion

Slide 56 · Clinical priorities differ among MEN1 lesions

Compartment

Primary injury mechanism

Core clinical priority

Parathyroid

Chronic PTH excess

Calcium and renal / skeletal effects

Gastrinoma

Excess gastric acid

Ulcer complications

Insulinoma

Endogenous hypoglycemia

Neuroglycopenic risk

PanNEN with aggressive behavior

Tumor invasion / spread

Extent and progression

Pituitary

Hormone excess / mass effect

Endocrine + neuro-ophthalmic assessment

Slide 57 · MEN1 and MEN2 are distinct genetic syndromes

Feature

MEN1

MEN2A (contrast)

Gene

MEN1 tumor suppressor

RET proto-oncogene

Typical endocrine sites

Parathyroid, duodenum/pancreas, pituitary

Medullary thyroid carcinoma, pheochromocytoma ± parathyroid

Principal mechanism

Altered menin function

Activating RET signaling

Most useful discriminator

Enteropancreatic/pituitary pattern

Medullary thyroid carcinoma + adrenal chromaffin tumor

Slide 58 · MEN1-like disease can have another genetic basis

MEN1

Germline MEN1 alteration.

Menin-related tumor susceptibility.

Classic three-P distribution.

MEN1 phenocopy / MEN4 context

CDKN1B changes can create a MEN1-like clinical picture.

Gene-based distinction matters.

Clinical overlap is not molecular identity.

Slide 59 · Parathyroid carcinoma suggests an alternate syndrome

Classic MEN1 parathyroid disease includes adenomas and hyperplasia.

An invasive parathyroid carcinoma warrants consideration of distinct genetic predispositions.

The textbook associates CDC73 defects with hyperparathyroidism–jaw tumor syndrome.

Do not assign every familial parathyroid tumor to MEN1.

Slide 60 · Distinguish multiple tumors from one multihormonal tumor

MEN1 multisite neoplasia

Independent lesions may occur in different endocrine organs.

Several hormonal syndromes may coexist.

Multihormonal PanNEN

One tumor may produce several hormones.

Multiple hormone assays do not prove multiple neoplasms.

Slide 61 · Suspected MEN1: Reasoning from phenotype to genotype

Identify characteristic endocrine lesions

Establish each hormone syndrome

Assess multifocal / multigland distribution

Evaluate inherited predisposition

Conceptual evaluation flow; No surveillance or germline testing thresholds asserted.

Slide 62 · Case: Ulcer disease and biochemical hyperparathyroidism

A patient with recurrent severe peptic ulceration also has PTH-dependent hypercalcemia. Imaging shows a small duodenal endocrine mass.

Which combination most strongly favors a syndromic hypothesis?

Coexisting primary hyperparathyroidism and a gastrinoma-pattern lesion strongly suggest the MEN1 phenotype.

Slide 63 · Case: Normal-looking cells, consequential disease

A pancreatic neuroendocrine lesion shows relatively uniform cells, but imaging detects additional foci and a distant deposit.

Which inference would be unsafe?

That bland cytology guarantees biologic indolence. Multifocality and metastatic status must be assessed independently.

Slide 64 · Case: A single MEN1 feature is not diagnostic

An older adult has a solitary parathyroid adenoma without relevant family history, pancreatic lesions or pituitary manifestations.

Which conclusion is most defensible?

A sporadic adenoma is plausible. One parathyroid lesion alone does not establish inherited MEN1.

Slide 65 · MEN1: Clinicopathologic synthesis

Genetic substrate

Germline MEN1; Altered menin

Tissue phenotype

Multisite, often multifocal tumors

Clinical outcome

Hormonal syndromes ± malignant spread

Think in parallel: Genotype, morphology, and hormone physiology.

Slide 66 · Five findings that should remain linked

The three Ps: Parathyroid, enteropancreatic system and pituitary.

Primary hyperparathyroidism is common and usually the initial manifestation.

Duodenal gastrinomas and multifocal pancreatic lesions are important.

Prolactinoma is the characteristic pituitary lesion; Somatotroph tumors also occur.

Germline MEN1–menin dysfunction underlies a multisite neoplastic predisposition.

Slide 67 · Principal textbook references

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. (2026). The Endocrine System.

Relevant sections: Multiple Endocrine Neoplasia Syndromes; Multiple Endocrine Neoplasia, Type 1.

Relevant sections: Primary Hyperparathyroidism; Pancreatic Neuroendocrine Neoplasms.

Relevant sections: Lactotroph PitNET; Somatotroph PitNET.